Standards of Care

Girl in wheelchair talking with friend

This easy-to-understand guide provides a summary of the main recommendations for the care of individuals with 5q SMA (Types 1, 2, 3 and 4). These recommendations were detailed in two scientific articles in November 2017 by a group of global healthcare and patient specialists and combined into this handy paediatric reference guide into 2019. Click picture to download.

The consensus was that the most suitable intervention and care relied on the individual’s ‘functional capability’, which includes:

  • Their ability to sit, stand or walk,
  • The impact of SMA on their respiration,
  • Their ability to manage other daily activities.

However, since these publications, new drug treatments have brought about swift changes and many uncertainties. Healthcare professionals both in the country and abroad regularly reassess and discuss optimal care and management methods. Consequently, some recommendations are being updated. While the SoC still provides a valuable reference for families, the care and management of your child’s condition will be highly personalized, based on your child’s clinical team’s assessment and thorough discussion with you.

If you would like to read the details in the 2017 papers that formed the basis of this publication they can be found below:

However, since these publications, new drug treatments have brought about swift changes and many uncertainties. Healthcare professionals both in the country and abroad regularly reassess and discuss optimal care and management methods. Consequently, some recommendations are being updated. While the SoC still provides a valuable reference for families, the care and management of your child’s condition will be highly personalized, based on your child’s clinical team’s assessment and thorough discussion with you.

If you would like to read the complete and original publication from Treat NMD a fully online and indexed version of the standard of care can be found here.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more